Skip to main content

Table 6 Base case cost-effectiveness (95% CI) of ART compared with no-ART

From: Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia

Strategy Life time Cost $ Life time incremental cost$ Life years gain Incremental life years gain Cost effectiveness ($) Incremental Cost Effectiveness ratio (ICER $) % change from base case ICER
Undiscounted        
no-ART 265(86–1148)   2.3(1.95–2.73)   114(38–504)   
ART 2479(1214–4828) 2215(771–4635) 9.4(8.67–10.05) 7.1(6.24–7.83) 265(130–513) 314(111–654)  
Discounted at 3%        
no-ART 247(80–1008)   2.2(1.83–2.56)   114(37–471)   
ART 2028(1000–3868) 1780(577–3710) 7.7(7.15–8.18) 5.5(4.85–6.13) 265(131–508) 325(106–680) 3.5